Developments in the treatment of patients with mesothelioma is ongoing and includes many new and experimental therapies that attack tumor cells of malignant mesothelioma without using chemotherapy. This treatment is being studied for the use of anti-angiogenesis in tumors of mesothelioma.
What is Angiogenesis, and How Does it Apply to Mesothelioma Tumors?
In its simplest form definitions, angiogenesis is the production of new blood vessels. Basic anatomy and professor of human biology in which the body grows, so has the demand for new vessels and arteries, that the living parts of the body requires a flow of oxygenated blood to survive.
It's no different for tumors that require mesothelioma new network of blood vessels for growth and survival. This is where the anti-angiogenesis drugs are associated with the treatment of patients with mesothelioma, a process described in the next section.
Treatment of Mesothelioma - New Anti-angiogenesis Drug Therapy
The researchers are currently using an anti-angiogenic drugs targeting the creation of blood vessels in the tumors of mesothelioma. In short, I hope that these drugs inhibit the growth of blood vessels mesothelioma patients with malignant mesothelioma tumors to grow their bodies (often in the lungs due to prolonged exposure to asbestos).
Research and testing of anti-angiogenesis in several types of incurable cancer was started and mesothelioma web writing that"esearchers are studying both natural and synthetic inhibitors of anti-angiogenesis, and although many these substances is still available only in clinical trials were the first anti-angiogenic drug, bevacizumab (Avastin), approved by the Food and Drug Administration (February 2004) for use in the treatment of colorectal cancer metastasis. A Phase II study of cisplatin and pemetrexed mesothelioma bevacizumabfor untreated and a phase II study of bevacizumab and erlotinib in previously treated mesothelioma"in trials continue mesothelioma is ongoing.
How Anti-angiogenensis Drugs Target Mesothelioma Tumors
Malignant cells of mesothelioma cancer and vascular networks, they need to survive, consists of a number of essential proteins. According Mesothelioma Web "One of the most important protein in the growth of new blood vessels, called vascular endothelial growth factor or VEGF, secreted by certain cancer cells. It appears that VEGF plays an important role in the growth of malignant mesothelioma. VEGF attach a protein, or VEGF receptor on the surface of endothelial cells nearby, then signals the control center of the cell to begin the growth and formation of new blood vessels. "
Several anti-angiogenesis drugs used in clinical trials have shown that targeting pathways inhibits VEGF and VEGF receptors. Although anti-angiogenesis drugs have not yet developed as a proven treatment for mesothelioma patients, research is underway.